Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PAN-301-1 in Prostate Cancer
NCT03120832Phase 1Completed
- Sponsor
- Sensei Biotherapeutics
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, Single Strain Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNS-301 in prostate cancer (PCa), sponsored by Sensei Biotherapeutics. Primary endpoint: Dose-limiting Toxicity at 21 days. Started Dec 2016; status: completed.
02
Drugs
SNS-301
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03120832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120832.